Skip to main content
TCNNF
OTC Life Sciences

Trulieve Authorizes $50M Share Repurchase Program, Up to 5% of Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$12.22
Mkt Cap
$2.5B
52W Low
$3.25
52W High
$13
52W Position info
276% above low
Off High info
6.0% below high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

TCNNF has more than doubled off its 52-week low of $3.25 on elevated volume (3.0× avg).

Summary

Trulieve's Board has authorized a new share repurchase program of up to $50 million, or 5% of its outstanding shares, over the next 12 months, reflecting confidence in the company's long-term value.


Key Events · Financing and Capital Events · TCNNF

  • Share Repurchase Program Authorized

    The Board authorized a program to repurchase up to $50 million or 8,495,038 subordinate voting shares (5% of outstanding shares as of June 8, 2026).

  • Program Duration and Intent

    The program will run for 12 months, expiring on June 16, 2027, with repurchased shares to be cancelled. Management views this as a tool to deliver shareholder value.

  • Capital Allocation Strategy

    This initiative follows the company's recent return to GAAP net profitability in Q1 2026, indicating a strategic use of capital to enhance shareholder returns.


Analysis · TCNNF · Life Sciences

The Board's authorization of a $50 million share repurchase program, representing up to 5% of outstanding shares, signals management's confidence in the company's valuation. This move aims to enhance shareholder value by reducing the share count and is a significant capital allocation decision following the company's return to GAAP net profitability in Q1 2026.

How filings like this one have moved

In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCNNF was trading at $12.22 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $3.25 to $13.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCNNF - Latest Insights

TCNNF
Jun 04, 2026, 6:42 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.61
Real-time Price: $13.40 info
Change: +$4.79 (+56%) info
Market Cap: $2.221B info
TCNNF
May 07, 2026, 6:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.79
Real-time Price: $13.40 info
Change: +$3.61 (+37%) info
Market Cap: $2.221B info
TCNNF
May 07, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.79
Real-time Price: $13.40 info
Change: +$3.61 (+37%) info
Market Cap: $2.221B info
TCNNF
May 07, 2026, 6:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.79
Real-time Price: $13.40 info
Change: +$3.61 (+37%) info
Market Cap: $2.221B info
TCNNF
Mar 05, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.13
Real-time Price: $13.40 info
Change: +$7.27 (+119%) info
Market Cap: $2.221B info